- Home
- IBRX vs SGRY Comparison
IBRX vs SGRY Comparison
Compare IBRX & SGRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- SGRY
- Stock Information
- Founded
- IBRX 2014
- SGRY 2004
- Country
- IBRX United States
- SGRY United States
- Employees
- IBRX N/A
- SGRY N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- SGRY Hospital/Nursing Management
- Sector
- IBRX Health Care
- SGRY Health Care
- Exchange
- IBRX Nasdaq
- SGRY Nasdaq
- Market Cap
- IBRX 2.4B
- SGRY 2.7B
- IPO Year
- IBRX N/A
- SGRY 2015
- Fundamental
- Price
- IBRX $2.96
- SGRY $23.48
- Analyst Decision
- IBRX Strong Buy
- SGRY Buy
- Analyst Count
- IBRX 5
- SGRY 8
- Target Price
- IBRX $11.35
- SGRY $37.57
- AVG Volume (30 Days)
- IBRX 5.6M
- SGRY 878.6K
- Earning Date
- IBRX 03-03-2025
- SGRY 05-06-2025
- Dividend Yield
- IBRX N/A
- SGRY N/A
- EPS Growth
- IBRX N/A
- SGRY N/A
- EPS
- IBRX N/A
- SGRY N/A
- Revenue
- IBRX $14,745,000.00
- SGRY $3,114,300,000.00
- Revenue This Year
- IBRX $621.53
- SGRY $10.91
- Revenue Next Year
- IBRX $163.57
- SGRY $9.15
- P/E Ratio
- IBRX N/A
- SGRY N/A
- Revenue Growth
- IBRX 2270.58
- SGRY 13.52
- 52 Week Low
- IBRX $2.28
- SGRY $19.50
- 52 Week High
- IBRX $10.53
- SGRY $33.97
- Technical
- Relative Strength Index (RSI)
- IBRX 49.28
- SGRY 38.97
- Support Level
- IBRX $2.69
- SGRY $23.85
- Resistance Level
- IBRX $3.47
- SGRY $24.31
- Average True Range (ATR)
- IBRX 0.23
- SGRY 0.45
- MACD
- IBRX 0.04
- SGRY -0.06
- Stochastic Oscillator
- IBRX 35.44
- SGRY 8.20
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About SGRY Surgery Partners Inc.
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It operates in two segments: Surgical Facility Services and Ancillary Services out of which the Surgical Facility Services segment accounts for the majority of revenue.